Spinal Muscular Atrophy Program Research and Innovation

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Spinal Muscular Atrophy Program

  • 1-617-355-6388
  • International: +1-617-355-5209

Research on spinal muscular atrophy (SMA) is moving forward quickly. The search for a treatment or cure has gained momentum among university researchers, pharmaceutical companies, and funding agencies.

Here at Boston Children’s Hospital, we are actively involved in several areas of research on SMA:

  • natural history studies
  • clinical trials
  • basic scientific studies
  • medication trials

Natural history studies

Researchers have found that in order to better understand SMA and to plan clinical trials, we need to learn more about the progression, or “natural history,” of the disease. So members of our Spinal Muscular Atrophy Program at Children’s are participating in a long-term natural history study.

This study was conducted through the Pediatric Neuromuscular Clinical Research (PNCR) Network,  a collaboration between doctors and families at Boston Children’s Hospital, Columbia University Medical Center and Children’s Hospital of Philadelphia. The goal of this group has always been is to offer a medication trial. The results of the 12-month natural history study have been published already and the 12-month to 48-month results will be published in the near future.

Clinical trials

When researchers and physicians conduct clinical trials of new drugs and therapies, they need to have standardized systems for measuring the symptoms of children with SMA so they can know whether the new therapy is helping. Unfortunately, the measurement systems, or “outcome measures,” that are currently available are not perfect. As a result, the specialists in our Spinal Muscular Atrophy Program at Boston Children’s have developed new outcome measures, some of which are now being used by other centers. 

Basic scientific studies

Sahin Boston ChildrensResearchers at Boston Children’s are working to better understand SMA at the cellular and molecular level. In the laboratory of Boston Children’s neurologist Mustafa Sahin, MD, PhD, scientists are studying proteins that are associated with the SMA protein, SMN. While most forms of SMA are related to alterations in the SMN protein, these other proteins are thought to play important roles in the disease.

Medication trials

We completed a phase I drug study with Isis Pharmaceuticals to help test the safety of a new drug that could help people with SMA. This study looked at the safety and tolerability of a new drug that had been shown to increase the production of the survival of motor neuron (SMN) protein. In 95 percent of SMA cases, the SMN1 gene is absent.  By inducing a second gene, known as SMN2, to produce more protein, this drug could potentially help reduce the symptoms of SMA and have beneficial therapeutic outcomes .    

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944